Interim multicenter European data presented for the IDH-mutant glioma program show serial amino-acid PET can detect early metabolic responses to vorasidenib sooner than structural MRI. In patients assessed with PET Response Assessment in Neuro-Oncology 1.0, partial responses occurred in 29% versus 6% by RANO 2.0. The median time to response was 4 months by PET RANO 1.0 compared with 8 months by RANO 2.0, with metabolic tumor volume change driving early classification. Stable disease rates were also higher in PET RANO 1.0 assessments (62% vs 74%), while progressive disease percentages remained similar. Researchers at Erasmus MC in Rotterdam emphasized the clinical constraint that MRI tumor volume can change slowly under therapy, motivating PET-based earlier readouts.